Examples of 'pertuzumab' in a sentence
Meaning of "pertuzumab"
Pertuzumab (adjective): Referring to a type of monoclonal antibody used in cancer treatment
Show more definitions
- A monoclonal antibody being developed as a drug to slow tumour growth.
How to use "pertuzumab" in a sentence
Basic
Advanced
pertuzumab
Pertuzumab may elicit severe diarrhoea.
The metabolism of pertuzumab has not been directly studied.
Pertuzumab was generally well tolerated.
The maximum tolerated dose of pertuzumab has not been determined.
Pertuzumab works by recognizing and attaching to these cancer cells.
The active substance is pertuzumab.
Pertuzumab displayed linear pharmacokinetics within the recommended dose range.
Perjeta is a cancer medicine that contains the active substance pertuzumab.
Lapatinib and pertuzumab were not different from vehicle in this study.
Pregnancy status must be verified before the start of pertuzumab treatment.
Pertuzumab is also an option for patients who have not already received it.
No specific fertility studies in animals have been performed to evaluate the effect of pertuzumab.
Pertuzumab is one of many newer biologic agents used to treat breast cancer.
There is limited amount of data from the use of pertuzumab in pregnant women.
Dose adjustments of pertuzumab are not needed in patients with mild or moderate renal impairment.
See also
When the diarrhoea is under control treatment with pertuzumab may be reinstated.
Do not mix Pertuzumab with other drugs.
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab.
Your unborn baby could be harmed if you use pertuzumab while you are pregnant.
Antibodies to pertuzumab were not detected Allison et al.
Dose reductions are not recommended for Pertuzumab.
Pertuzumab should be withheld or discontinued if Trastuzumab treatment is withheld or discontinued.
No drug overdoses have been reported with Pertuzumab to date.
Efficacy data for Pertuzumab is provided in the examples herein.
Studies have not been performed to evaluate the mutagenic potential of Pertuzumab.
The effects of Pertuzumab are likely to be present during all trimesters of pregnancy.
No dedicated renal impairment trial for Pertuzumab has been conducted.
Patients treated with pertuzumab can be selected for therapy based on HER activation or dimerization.
There was no evidence of any PK interaction between pertuzumab and any of these agents.
The Pertuzumab and Trastuzumab alone samples served as controls.
No dose adjustment was permitted for Pertuzumab or Trastuzumab.
Summary of the results Pertuzumab trough concentrations are lower in GC compared to MBC.
Field of the Invention The present invention concerns fixed dosing of pertuzumab.
Differences between trastuzumab and pertuzumab functions are illustrated in Fig . 6.
Figure 6 compares various activities of trastuzumab and pertuzumab.
Like trastuzumab, pertuzumab is directed against the extracellular domain of HER2.
The Trastuzumab alone showed little activity in the Pertuzumab potency assay.
Optionally, Pertuzumab is administered concurrently with the carboplatin-based chemotherapy.
In cynomolgus monkeys, weekly intravenous administration of pertuzumab at doses up to.
The PK of pertuzumab in these studies was comparable to those observed in single-agent studies.
In some embodiments, the additional therapeutic agent is pertuzumab and docetaxel.
Pertuzumab stops HER2 producing signals that cause the cancer cells to grow.
It is recommended to apply fixed-dosing regimens for pertuzumab in cancer patients.
Pertuzumab is a sterile, clear to slightly opalescent, colorless to pale yellow liquid for IV infusion.
Therefore, there is no need to adjust the dosage of pertuzumab based on these covariates.
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Optionally the Pertuzumab and Trastuzumab are co-administered to the patient from a single intravenous bag.
A HER2 antibody of particular interest herein is pertuzumab.
Pertuzumab is a fully humanized recombinant monoclonal antibody directed against the extracellular domain of HER2.
In the other arm, patients are given either placebo or Pertuzumab.
